Brain-Derived neurotrophic factor (BDNF) plasma level increases in patients with resistant schizophrenia treated with electroconvulsive therapy (ECT)

References

• Akyol ES, Albayrak Y, Beyazyüz M, Aksoy N, Kuloglu M, Hashimoto K. 2015. Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome. Neuropsychiatr Dis Treat. 11:865–872.
   PubMed Web of Science ®Google Scholar
• Association, A. P. 2014. Diagnostic and Statistical Manual of Mental Disorders, (DSM-5).
   Google Scholar
• Bathina S, DAS UN. 2015. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 11(6):1164–1178.
   PubMed Web of Science ®Google Scholar
• Dall’Agnol L, Medeiros LF, Torres ILS, Deitos A, Brietzke A, Laste G, de Souza A, Vieira JL, Fregni F, Caumo W. 2014. Repetitive transcranial magnetic stimulation increases the corticospinal inhibition and the brain-derived neurotrophic factor in chronic myofascial pain syndrome: an explanatory double-blinded, randomized, sham-controlled trial. J Pain. 15(8):845–855.
   PubMed Web of Science ®Google Scholar
• Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turck CW, Nardin P, Gonçalves CA. 2015. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry. 20(9):1108–1119.
   PubMed Web of Science ®Google Scholar
• Fernandes BS, Berk M, Turck CW, Steiner J, Gonçalves C-A. 2014. Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Mol Psychiatry. 19(7):750–751.
   PubMed Web of Science ®Google Scholar
• Fisher M, Mellon SH, Wolkowitz O, Vinogradov S. 2016. Neuroscience-informed auditory training in schizophrenia: a final report of the effects on cognition and serum brain-derived neurotrophic factor. Schizophr Res Cogn. 3:1–7.  doi:10.1016/j.scog.2015.10.006
   PubMedGoogle Scholar
• Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. 2011. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry. 16(9):960–972.
   PubMed Web of Science ®Google Scholar
• Heitz U, Papmeyer M, Studerus E, Egloff L, Ittig S, Andreou C, Vogel T, Borgwardt S, Graf M, Eckert A, et al. 2019. Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients. World J Biol Psychiatry. 20(7):545–554.
   PubMed Web of Science ®Google Scholar
• IBM 2011. IBM SPSS Statistics for Windows. 20.0 ed. Armonk, NY: IBM Corp.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Kordi-Tamandani DM, Sahranavard R, Torkamanzehi A. 2012. DNA methylation and expression profiles of the brain-derived neurotrophic factor (BDNF) and dopamine transporter (DAT1) genes in patients with schizophrenia. Mol Biol Rep. 39(12):10889–10893.
   PubMed Web of Science ®Google Scholar
• Kurita M, Nishino S, Kato M, Numata Y, Sato T. 2012. Plasma brain-derived neurotrophic factor levels predict the clinical outcome of depression treatment in a naturalistic study. PLOS One. 7(6):e39212.
   PubMed Web of Science ®Google Scholar
• Lee BH, Kim YK. 2009. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. Neuropsychobiology. 59(1):51–58. Epub 2009 Mar 6. PMID: 19270464.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, Mcglashan TH, Miller AL, Perkins DO, Kreyenbuhl J. 2004. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 161(2 Suppl):1–56.
   PubMed Web of Science ®Google Scholar
• Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. 2009. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl. 119(438):7–14.
   Google Scholar
• Li J, Ye F, Xiao W, Tang X, Sha W, Zhang X, Wang J. 2016. Increased serum brain-derived neurotrophic factor levels following electroconvulsive therapy or antipsychotic treatment in patients with schizophrenia. Eur Psychiatr. 36:23–28.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Ricci V, DI Nicola M, Caltagirone C, Bria P, Angelucci F. 2011. Brain-derived neurotrophic factor and electroconvulsive therapy in a schizophrenic patient with treatment-resistant paranoid-hallucinatory symptoms. J Ect. 27:e44–e46.
   Google Scholar
• Mindt S, Neumaier M, Hellweg R, Sartorius A, Kranaster L. 2020. Brain-derived neurotrophic factor in the cerebrospinal fluid increases during electroconvulsive therapy in patients with depression: a preliminary report. J Ect. 36(3):193–197.
   PubMed Web of Science ®Google Scholar
• NICE 2003. Guidance on the use of electroconvulsive therapy. Available: https://www.nice.org.uk/guidance/ta59/chapter/1-Guidance. [Accessed 2020].
   Google Scholar
• Niitsu T, Ishima T, Yoshida T, Hashimoto T, Matsuzawa D, Shirayama Y, Nakazato M, Shimizu E, Hashimoto K, Iyo M. 2014. A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia. Psychiatry Res. 215(2):268–273.
   PubMed Web of Science ®Google Scholar
• Peng S, Li W, Lv L, Zhang Z, Zhan X. 2018. BDNF as a biomarker in diagnosis and evaluation of treatment for schizophrenia and depression. Discov Med. 26(143):127–136.
   PubMed Web of Science ®Google Scholar
• Perkovic MN, Erjavec GN, Strac DS, Uzun S, Kozumplik O, Pivac N. 2017. Theranostic biomarkers for schizophrenia. IJMS. 18(4):733.
   Google Scholar
• Polyakova M, Schroeter ML, Elzinga BM, Holiga S, Schoenknecht P, DE Kloet ER, Molendijk ML. 2015. Brain-derived neurotrophic factor and antidepressive effect of electroconvulsive therapy: systematic review and meta-analyses of the preclinical and clinical literature. PLoS One. 10(11):e0141564–e0141564.
   Web of Science ®Google Scholar
• Pompili M, Lester D, Dominici G, Longo L, Marconi G, Forte A, Serafini G, Amore M, Girardi P. 2013. Indications for electroconvulsive treatment in schizophrenia: a systematic review. Schizophr Res. 146(1–3):1–9.
   PubMed Web of Science ®Google Scholar
• Reis HJ, Nicolato R, Barbosa IG, Teixeira DO, Prado PH, Romano-Silva MA, Teixeira AL. 2008. Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. Neurosci Lett. 439(2):157–159.
   PubMed Web of Science ®Google Scholar
• Richard Jaffe MD, Philadelphia PA. 2002. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging: a task force report of the American Psychiatric Association, 2nd ed. AJP. 159(2):331–331.
   Google Scholar
• Rizos EN, Rontos I, Laskos E, Arsenis G, Michalopoulou PG, Vasilopoulos D, Gournellis R, Lykouras L. 2008. Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 32(5):1308–1311.
   PubMed Web of Science ®Google Scholar
• Rizos E, Papathanasiou MA, Michalopoulou PG, Laskos E, Mazioti A, Kastania A, Vasilopoulou K, Nikolaidou P, Margaritis D, Papageorgiou C, et al. 2014. A longitudinal study of alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsychotics in a sample of first-episode patients with schizophrenia. PLoS One. 9(2):e87997.
   PubMed Web of Science ®Google Scholar
• Sanghani SN, Petrides G, Kellner CH. 2018. Electroconvulsive therapy (ECT) in schizophrenia: a review of recent literature. Curr Opin Psychiatry. 31(3):213–222.
   PubMed Web of Science ®Google Scholar
• Sinclair DJ, Zhao S, Qi F, Nyakyoma K, Kwong JS, Adams CE. 2019. Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 3:CD011847–CD011847.
   PubMedGoogle Scholar
• Tharyan P, Adams CE. 2005. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev. :Cd000076.
   PubMedGoogle Scholar
• Vanicek T, Kranz GS, Vyssoki B, Komorowski A, Fugger G, Höflich A, Micskei Z, Milovic S, Lanzenberger R, Eckert A, et al. 2019. Repetitive enhancement of serum BDNF subsequent to continuation ECT. Acta Psychiatr Scand. 140:426–434. doi: 10.1111/acps.13080
   Google Scholar
• Weickert CS, Weickert TW. 2016. What's hot in schizophrenia research? Psychiatr Clin North Am. 39(2):343–351.
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu Y, Wang G, Hei G, Wang X, Li R, Li L, Wu R, Zhao J. 2019. Brain-derived neurotrophic factor is associated with cognitive impairments in first-episode and chronic schizophrenia. Psychiatry Res. 273:528–536.
   PubMed Web of Science ®Google Scholar